The first Alzheimer's imaging agent, Amyvid, became available in the US in April 2012 and, though the market for these products was valued at less than $3 million in 2013, increased coverage and the launch of the first DMT for AD will help the market to experience rapid expansion through 2022.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Alzheimer's imaging agents in the US across a 10-year period.
Geographies Covered: US
Procedures Covered: DRG's analysis uses the following breakdown of procedures:
Beta-Amyloid Imaging Procedures
Other Imaging Procedures
Products Covered: DRG's analysis uses the following breakdown of products in the market:
Alzheimer's Imaging Agents
Nuclear Medicine Systems
Market Forecast Features: Based on primary research with industry professionals, DRG uses its proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, installed base, and market values over a 10-year period (2012–2022).
Competitive Analysis: DRG provides a detailed analysis of the competitive landscape and market shares for leading competitors.